Literature DB >> 19096842

Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate.

Gaetano Paone1, Emmanuel Itti, Corinne Haioun, Philippe Gaulard, Jehan Dupuis, Chieh Lin, Michel Meignan.   

Abstract

PURPOSE: To assess, in patients with diffuse large B-cell lymphoma (DLBCL), whether the low sensitivity of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for bone marrow assessment may be explained by histological characteristics of the cellular infiltrate.
METHODS: From a prospective cohort of 110 patients with newly diagnosed aggressive lymphoma, 21 patients with DLBCL had bone marrow involvement. Pretherapeutic FDG-PET images were interpreted visually and semiquantitatively, then correlated with the type of cellular infiltrate and known prognostic factors.
RESULTS: Of these 21 patients, 7 (33%) had lymphoid infiltrates with a prominent component of large transformed lymphoid cells (concordant bone marrow involvement, CBMI) and 14 (67%) had lymphoid infiltrates composed of small cells (discordant bone marrow involvement, DBMI). Only 10 patients (48%) had abnormal bone marrow FDG uptake, 6 of the 7 with CBMI and 4 of the 14 with DBMI. Therefore, FDG-PET positivity in the bone marrow was significantly associated with CBMI, while FDG-PET negativity was associated with DBMI (Fisher's exact test, p=0.024). There were no significant differences in gender, age and overall survival between patients with CBMI and DBMI, while the international prognostic index was significantly higher in patients with CBMI.
CONCLUSION: Our study suggests that in patients with DLBCL with bone marrow involvement bone marrow FDG uptake depends on two types of infiltrate, comprising small (DBMI) or large (CBMI) cells. This may explain the apparent low sensitivity of FDG-PET previously reported for detecting bone marrow involvement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19096842     DOI: 10.1007/s00259-008-1021-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  22 in total

1.  FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.

Authors:  F Moog; J Kotzerke; S N Reske
Journal:  J Nucl Med       Date:  1999-09       Impact factor: 10.057

2.  Utility of FDG-PET scanning in lymphoma by WHO classification.

Authors:  Rebecca Elstrom; Liang Guan; Gary Baker; Khozaim Nakhoda; Jo-Anne Vergilio; Hongming Zhuang; Stephanie Pitsilos; Adam Bagg; Lisa Downs; Amit Mehrotra; Scott Kim; Abass Alavi; Stephen J Schuster
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

3.  Can [18F]fluorodeoxyglucose positron emission tomography imaging complement biopsy results from the iliac crest for the detection of bone marrow involvement in patients with malignant lymphoma?

Authors:  David Fuster; Stephen Chiang; Charalambos Andreadis; Liang Guan; Hongming Zhuang; Stephen Schuster; Abass Alavi
Journal:  Nucl Med Commun       Date:  2006-01       Impact factor: 1.690

4.  18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.

Authors:  Emilios E Pakos; Andreas D Fotopoulos; John P A Ioannidis
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

5.  Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.

Authors:  Chieh Lin; Emmanuel Itti; Corinne Haioun; Yolande Petegnief; Alain Luciani; Jehan Dupuis; Gaetano Paone; Jean-Noël Talbot; Alain Rahmouni; Michel Meignan
Journal:  J Nucl Med       Date:  2007-09-14       Impact factor: 10.057

6.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

Authors:  F Moog; M Bangerter; J Kotzerke; A Guhlmann; N Frickhofen; S N Reske
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

7.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading.

Authors:  S Wöhrer; U Jaeger; K Kletter; A Becherer; A Hauswirth; K Turetschek; M Raderer; M Hoffmann
Journal:  Ann Oncol       Date:  2006-02-23       Impact factor: 32.976

10.  Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.

Authors:  Vincent Ribrag; Daniel Vanel; Sophie Leboulleux; Jean Lumbroso; Dominique Couanet; Guillaume Bonniaud; Anne Aupérin; Florence Masson; Jacques Bosq; Véronique Edeline; Christophe Fermé; Frédéric Pigneur; Martin Schlumberger
Journal:  Eur J Radiol       Date:  2007-07-24       Impact factor: 3.528

View more
  16 in total

Review 1.  Discordant bone marrow involvement in non-Hodgkin lymphoma.

Authors:  Jennifer Brudno; Tamar Tadmor; Stefania Pittaluga; Alina Nicolae; Aaron Polliack; Kieron Dunleavy
Journal:  Blood       Date:  2015-12-17       Impact factor: 22.113

Review 2.  FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Thomas C Kwee; Bart de Keizer; Rob Fijnheer; John M H de Klerk; Rutger A J Nievelstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-27       Impact factor: 9.236

3.  Usefulness of (18)F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin's Lymphoma.

Authors:  Yukyung Lee; Kyung Hoon Hwang; Junshik Hong; Jinny Park; Jae Hoon Lee; Jeong Yeal Ahn; Ji Hyun Kim; Haejun Lee; Seog Gyun Kim; Ji Young Shin
Journal:  Nucl Med Mol Imaging       Date:  2012-07-18

4.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

Authors:  Sally F Barrington; N George Mikhaeel; Lale Kostakoglu; Michel Meignan; Martin Hutchings; Stefan P Müeller; Lawrence H Schwartz; Emanuele Zucca; Richard I Fisher; Judith Trotman; Otto S Hoekstra; Rodney J Hicks; Michael J O'Doherty; Roland Hustinx; Alberto Biggi; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

6.  Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.

Authors:  Myriam Sasanelli; Michel Meignan; Corinne Haioun; Alina Berriolo-Riedinger; René-Olivier Casasnovas; Alberto Biggi; Andrea Gallamini; Barry A Siegel; Amanda F Cashen; Pierre Véra; Hervé Tilly; Annibale Versari; Emmanuel Itti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-06       Impact factor: 9.236

Review 7.  Positron emission tomographic scans in lymphoma: convention and controversy.

Authors:  Stephen M Ansell; James O Armitage
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

Review 8.  FDG-PET imaging in hematological malignancies.

Authors:  L Valls; C Badve; S Avril; K Herrmann; P Faulhaber; J O'Donnell; N Avril
Journal:  Blood Rev       Date:  2016-04-16       Impact factor: 8.250

Review 9.  Current role of FDG PET/CT in lymphoma.

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-12       Impact factor: 9.236

Review 10.  Radionuclide imaging of bone marrow disorders.

Authors:  Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.